Dan Lungulescu

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma

Tudor–Eliade Ciuleanu, I. Bazin, Dan Lungulescu et al. · Annals of Oncology · 2016 · 50 citations · Full text

Hepatology, Medicine, Clinical Trials +8

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations

Breast Oncology, Medicine, Primary Analysis +7

Clinically relevant bleeding in cancer patients treated for venous thromboembolism from the CATCH study

Pieter W. Kamphuisen, A.Y.Y. Lee, Guy Meyer et al. · Journal of Thrombosis and Haemostasis · 2018 · 37 citations · Full text

Thrombosis, Pulmonary Embolism, Venous Thrombosis +13

Determination of autophagy gene ATG16L1 polymorphism in human colorectal cancer.

Elena‐Raluca Nicoli, T Dumitrescu, Florin‐Dan Popescu et al. · PubMed · 2014 · 29 citations

Cell Autophagy, Autoimmune Disease, Medicine +14